Agios Pharmaceuticals, Inc.
- AGIO
- NASDAQ
- Biotechnology
- Metabolism-Based Biotech
- Rare Disease Therapeutics
$34.90
Today +11.43%Quote Oct 19, 2026, 08:00 PM UTC
−6.81%over the last month
Max drawdown −13.6%From 1-month high −10.4%3 months −21.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
540
Market value
$2.08B
Quote Oct 19
Floor
$34.03
2.5% below price
Resistance
$35.59
2.0% above price
Price vs analyst targets
29 analysts
Lowest target
$32.00Highest target
$55.00
$32.00Highest target
$55.00
- Price $34.90
- Average target $41.33
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 18% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AGIOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free